Literature DB >> 28041986

Insomnia symptoms with objective short sleep duration are associated with systemic inflammation in adolescents.

Julio Fernandez-Mendoza1, Joshua H Baker2, Alexandros N Vgontzas2, Jordan Gaines2, Duanping Liao3, Edward O Bixler2.   

Abstract

Inflammation has been suggested as a potential pathway by which insomnia and short sleep can affect risk of morbidity in adults. However, few studies have examined the association of insomnia with inflammation in adolescents, despite accumulating evidence that pathophysiologic changes may already occur during this critical developmental period. The present study sought to examine the association of insomnia symptoms with systemic inflammation and the role of objective sleep duration in this association. Participants were 378 adolescents (16.9±2.3y, 45.8% female) from the Penn State Child Cohort, a population-based sample who underwent 9-h polysomnography (PSG) followed by a single fasting blood draw to assess plasma levels of C-reactive protein (CRP) and other inflammatory markers. Insomnia symptoms were defined by a self-report of difficulties falling and/or staying asleep, while objective sleep duration groups were defined as a PSG total sleep time ⩾8, 8-7, and ⩽7h. We assessed the association of insomnia symptoms, objective sleep duration, and their interaction with inflammatory markers, while adjusting for multiple potential confounders. Adolescents reporting insomnia symptoms had significantly higher levels of CRP compared to controls and a significant interaction (p<0.01) showed that objective sleep duration modified this association. Elevated CRP was present in adolescents with insomnia symptoms and ⩽7h of sleep (1.79mg/L) as compared to controls or adolescents with insomnia symptoms and ⩾8h of sleep (0.90mg/L and 0.98mg/L, respectively) or controls with ⩽7h of sleep (0.74mg/L; all p-values <0.01). In sum, insomnia symptoms with objective short sleep duration are associated with systemic inflammation as early as adolescence. This study suggests that chronic low-grade inflammation may be a common final pathway towards morbidity in adulthood in this insomnia phenotype. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adolescents; C-reactive protein; Inflammation; Insomnia symptoms; Short sleep duration

Mesh:

Substances:

Year:  2016        PMID: 28041986      PMCID: PMC5316336          DOI: 10.1016/j.bbi.2016.12.026

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  34 in total

Review 1.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention.

Authors:  Paul M Ridker
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

Review 2.  Insomnia with objective short sleep duration: the most biologically severe phenotype of the disorder.

Authors:  Alexandros N Vgontzas; Julio Fernandez-Mendoza; Duanping Liao; Edward O Bixler
Journal:  Sleep Med Rev       Date:  2013-02-16       Impact factor: 11.609

Review 3.  Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation.

Authors:  Michael R Irwin; Richard Olmstead; Judith E Carroll
Journal:  Biol Psychiatry       Date:  2015-06-01       Impact factor: 13.382

4.  Leptin and hunger levels in young healthy adults after one night of sleep loss.

Authors:  Slobodanka Pejovic; Alexandros N Vgontzas; Maria Basta; Marina Tsaoussoglou; Emmanuel Zoumakis; Angeliki Vgontzas; Edward O Bixler; George P Chrousos
Journal:  J Sleep Res       Date:  2010-12       Impact factor: 3.981

Review 5.  IL-6 and its circadian secretion in humans.

Authors:  A N Vgontzas; E O Bixler; H-M Lin; P Prolo; G Trakada; G P Chrousos
Journal:  Neuroimmunomodulation       Date:  2005       Impact factor: 2.492

6.  Poor sleep as a pathophysiological pathway underlying the association between stressful experiences and the diurnal cortisol profile among children and adolescents.

Authors:  Jinshia Ly; Jennifer J McGrath; Jean-Philippe Gouin
Journal:  Psychoneuroendocrinology       Date:  2015-03-24       Impact factor: 4.905

7.  Chronic insomnia and activity of the stress system: a preliminary study.

Authors:  A N Vgontzas; C Tsigos; E O Bixler; C A Stratakis; K Zachman; A Kales; A Vela-Bueno; G P Chrousos
Journal:  J Psychosom Res       Date:  1998-07       Impact factor: 3.006

8.  Inflammation mediates the association between visceral adiposity and obstructive sleep apnea in adolescents.

Authors:  Jordan Gaines; Alexandros N Vgontzas; Julio Fernandez-Mendoza; Susan L Calhoun; Fan He; Duanping Liao; Marjorie D Sawyer; Edward O Bixler
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-09-20       Impact factor: 4.310

Review 9.  Hyperarousal and insomnia: state of the science.

Authors:  Michael H Bonnet; Donna L Arand
Journal:  Sleep Med Rev       Date:  2009-07-28       Impact factor: 11.609

Review 10.  The hyperarousal model of insomnia: a review of the concept and its evidence.

Authors:  Dieter Riemann; Kai Spiegelhalder; Bernd Feige; Ulrich Voderholzer; Mathias Berger; Michael Perlis; Christoph Nissen
Journal:  Sleep Med Rev       Date:  2009-05-28       Impact factor: 11.609

View more
  42 in total

Review 1.  Sleep disturbances and their impact in pediatric cystic fibrosis.

Authors:  Aarti Shakkottai; Louise M O'Brien; Samya Z Nasr; Ronald D Chervin
Journal:  Sleep Med Rev       Date:  2018-07-06       Impact factor: 11.609

Review 2.  Insomnia disorder in adolescence: Diagnosis, impact, and treatment.

Authors:  Massimiliano de Zambotti; Aimee Goldstone; Ian M Colrain; Fiona C Baker
Journal:  Sleep Med Rev       Date:  2017-07-01       Impact factor: 11.609

3.  CBT-I and the short sleep duration insomnia phenotype: a comment on Bathgate, Edinger and Krystal.

Authors:  Celyne H Bastien; Jason G Ellis; Michael Grandner
Journal:  Ann Transl Med       Date:  2017-08

4.  Total sleep time and kynurenine metabolism associated with mood symptom severity in bipolar disorder.

Authors:  Dahlia Mukherjee; Venkatesh Bassapa Krishnamurthy; Caitlin E Millett; Aubrey Reider; Adem Can; Maureen Groer; Dietmar Fuchs; Teodor T Postolache; Erika F H Saunders
Journal:  Bipolar Disord       Date:  2017-08-23       Impact factor: 6.744

5.  Cardiovascular autonomic dysfunction in insomnia patients with objective short sleep duration.

Authors:  Denise C Jarrin; Hans Ivers; Manon Lamy; Ivy Y Chen; Allison G Harvey; Charles M Morin
Journal:  J Sleep Res       Date:  2018-03-01       Impact factor: 3.981

6.  Sleep Quality Is Related to Worsening Knee Pain in Those with Widespread Pain: The Multicenter Osteoarthritis Study.

Authors:  Zhaoli Dai; Tuhina Neogi; Carrie Brown; Michael Nevitt; Cora E Lewis; James Torner; David T Felson
Journal:  J Rheumatol       Date:  2019-11-15       Impact factor: 4.666

7.  Nocturnal cognitive arousal is associated with objective sleep disturbance and indicators of physiologic hyperarousal in good sleepers and individuals with insomnia disorder.

Authors:  David A Kalmbach; Daniel J Buysse; Philip Cheng; Thomas Roth; Alexander Yang; Christopher L Drake
Journal:  Sleep Med       Date:  2019-11-14       Impact factor: 3.492

8.  Objective Sleep Characteristics and Cardiometabolic Health in Young Adolescents.

Authors:  Elizabeth M Cespedes Feliciano; Mirja Quante; Sheryl L Rifas-Shiman; Susan Redline; Emily Oken; Elsie M Taveras
Journal:  Pediatrics       Date:  2018-06-15       Impact factor: 7.124

9.  Natural history of insomnia symptoms in the transition from childhood to adolescence: population rates, health disparities, and risk factors.

Authors:  Julio Fernandez-Mendoza; Elizaveta Bourchtein; Susan Calhoun; Kristina Puzino; Cynthia K Snyder; Fan He; Alexandros N Vgontzas; Duanping Liao; Edward Bixler
Journal:  Sleep       Date:  2021-03-12       Impact factor: 5.849

10.  Sleep-disordered breathing in cystic fibrosis.

Authors:  Aarti Shakkottai; Samya Z Nasr; Fauziya Hassan; Sanaya Irani; Louise M O'Brien; Ronald D Chervin
Journal:  Sleep Med       Date:  2020-06-05       Impact factor: 3.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.